CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
REVENUES:
Total Revenues	$ 668	$ 546	$ 3,633	$ 2,686
OPERATING EXPENSES:
Research and Development	10,708	11,101	32,109	32,333
General and Administrative	3,640	3,403	10,833	12,207
Intangible Asset Impairment			3,500
Other Asset Impairment				1,800
Loss (Gain) on Fair Value Remeasurement of Contingent Consideration	662	(2,114)	(4,236)	(1,612)
Total Operating Expenses	15,010	12,390	42,206	44,728
Operating Loss	(14,342)	(11,844)	(38,573)	(42,042)
Investment and Other Income, Net	118	431	465	1,611
Net Loss Before Income Tax Benefit	(14,224)	(11,413)	(38,108)	(40,431)
Income Tax Benefit			228
Net Loss	$ (14,224)	$ (11,413)	$ (37,880)	$ (40,431)
Basic and Diluted Net Loss Per Common Share	$ (0.36)	$ (0.75)	$ (1.44)	$ (2.92)
Shares Used in Calculating Basic and Diluted Net Loss Per Share	39,278	15,282	26,303	13,854
COMPREHENSIVE LOSS:
Net Loss	$ (14,224)	$ (11,413)	$ (37,880)	$ (40,431)
Other Comprehensive Income (Loss):
Unrealized Gain (Loss) on Marketable Securities	14	(3)	(11)	52
Comprehensive Loss	(14,210)	(11,416)	(37,891)	(40,379)
Product Development and Licensing Agreements
REVENUES:
Total Revenues	12	55	2,297	379
Contracts and Grants
REVENUES:
Total Revenues	$ 656	$ 491	$ 1,336	$ 2,307